Analysis of Prethrombotic States in Patients with Malignant Tumors

Abstract

Background: This study aimed to investigate the incidence and risk factors for a prethrombotic state in patients with malignant tumors. Materials and Methods: Plasma d-dimer (D-D) in patients with malignant tumors was measured. Abnormal rates of D-D and possible risk factors like gender, age, type of tumor, and staging of tumor were analyzed. Results: Of 1,453 patients, 629 demonstrated plasma D-D abnormality (43.3%).The D-D abnormal rate of male patients (n=851, 43.5%) was not statistically significantly different from that for female patients (n=602, 43.0%) (p>0.05). D-D abnormal rate increased with age and was statistically significant among different age groups (p<0.05). Regarding staging of tumor, D-D abnormal rate in patients with phaseⅠ was 2.0%, 6.2% in phase Ⅱ, 47.6% in phase Ⅲ and 83.1% in phase Ⅳ, with statistically significant differences between phase Ⅲ and Ⅱ, as well as phase Ⅲ and Ⅳ (p<0.01). Conclusions: A prethrombotic state was closely related to malignancy of tumors. The risk factors for a prethrombotic state include age and tumor stage.

D‐dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress

“…Activated coagulation in cancer patients is implicated both in tumor progression and in development of VTE . While several studies have linked activated coagulation with many different cancer types, there are only few publications in malignant melanoma . To our knowledge, this is the first large‐scale cohort study examining the association between coagulation and survival in malignant melanoma patients.…”

The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma

“…Tumors have been reported to induce the inflammatory response, release cytokines, and injure vascular walls directly or indirectly by releasing tissue factor, which can activate the coagulation cascade and cause coagulation dysfunction. 30 Cancer patients have been shown to have a significantly higher D-dimer level than that of healthy controls 31 in situations of enhanced fibrin formation and fibrinolysis. Moreover, the D-dimer level has been reported to be not only an adverse prognostic factor but also a biomarker for the response to chemotherapy in several types of cancer.…”

Recurrent stroke in a patient of lung cancer without pulmonary mass

“…Both clinical and laboratory findings indicate that 90% of all metastatic cancers are accompanied by abnormalities in coagulation variables, for example, circulating D -dimers, thrombin–antithrombin complexes, tissue factor (TF), and other changes. [ 6 ] Cui et al [ 7 ] have shown that tumor cells could impair the balance of coagulation, anticoagulant, and fibrinolytic system through multiple mechanisms, which leads to prethrombotic state. Therefore, cancer patients are vulnerable to stroke.…”